These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 37453240

  • 1. Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091).
    Reijneveld JC, Machingura A, Coens C, Taphoorn MJB, Taal W, Clement PM, Idbaih A, de Vos FYF, Klein M, Wick W, Mulholland PJ, Lewis J, Golfinopoulos V, Ghislain I, Bottomley A, van den Bent MJ, EORTC Brain Tumor Group.
    Eur J Cancer; 2023 Sep; 190():112946. PubMed ID: 37453240
    [Abstract] [Full Text] [Related]

  • 2. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
    van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis J, Weller M, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C, Golfinopoulos V, Gorlia T, Idbaih A.
    Lancet Oncol; 2018 Sep; 19(9):1170-1179. PubMed ID: 30115593
    [Abstract] [Full Text] [Related]

  • 3. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
    Reijneveld JC, Taphoorn MJB, Coens C, Bromberg JEC, Mason WP, Hoang-Xuan K, Ryan G, Hassel MB, Enting RH, Brandes AA, Wick A, Chinot O, Reni M, Kantor G, Thiessen B, Klein M, Verger E, Borchers C, Hau P, Back M, Smits A, Golfinopoulos V, Gorlia T, Bottomley A, Stupp R, Baumert BG.
    Lancet Oncol; 2016 Nov; 17(11):1533-1542. PubMed ID: 27686943
    [Abstract] [Full Text] [Related]

  • 4. Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study).
    Ahn GS, Hwang K, Kim TM, Park CK, Chang JH, Jung TY, Kim JH, Nam DH, Kim SH, Yoo H, Hong YK, Kim EY, Lee DE, Joo J, Kim YJ, Choe G, Choi BS, Kang SG, Kim JH, Kim CY.
    Cancer Res Treat; 2022 Apr; 54(2):396-405. PubMed ID: 34237210
    [Abstract] [Full Text] [Related]

  • 5. Effect of low-dose bevacizumab on health-related quality of life in patients with recurrent high-grade glioma: A retrospective clinical study.
    Liao Y, Bai X, Cao Y, Zhang M.
    J Clin Neurosci; 2024 Feb; 120():196-203. PubMed ID: 38277995
    [Abstract] [Full Text] [Related]

  • 6. Improvement of health related quality of life in patients with recurrent glioma treated with bevacizumab plus daily temozolomide as the salvage therapy.
    Liu Y, Feng F, Ji P, Liu B, Ge S, Yang C, Lou M, Liu J, Li B, Gao G, Qu Y, Wang L.
    Clin Neurol Neurosurg; 2018 Jun; 169():64-70. PubMed ID: 29631109
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
    Clement PMJ, Dirven L, Eoli M, Sepulveda-Sanchez JM, Walenkamp AME, Frenel JS, Franceschi E, Weller M, Chinot O, De Vos FYFL, Whenham N, Sanghera P, Looman J, Kundu MG, Peter de Geus J, Nuyens S, Spruyt M, Gorlia T, Coens C, Golfinopoulos V, Reijneveld JC, van den Bent MJ.
    Eur J Cancer; 2021 Apr; 147():1-12. PubMed ID: 33601293
    [Abstract] [Full Text] [Related]

  • 9. The relationship between the degree of brain edema regression and changes in cognitive function in patients with recurrent glioma treated with bevacizumab and temozolomide.
    Wang X, Chen D, Qiu J, Li S, Zheng X.
    Quant Imaging Med Surg; 2021 Nov; 11(11):4556-4568. PubMed ID: 34737923
    [Abstract] [Full Text] [Related]

  • 10. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
    Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Glas M.
    J Clin Oncol; 2016 May 10; 34(14):1611-9. PubMed ID: 26976423
    [Abstract] [Full Text] [Related]

  • 11. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.
    Hanna C, Lawrie TA, Rogozińska E, Kernohan A, Jefferies S, Bulbeck H, Ali UM, Robinson T, Grant R.
    Cochrane Database Syst Rev; 2020 Mar 23; 3(3):CD013261. PubMed ID: 32202316
    [Abstract] [Full Text] [Related]

  • 12. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.
    Health Technol Assess; 2007 Nov 23; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [Abstract] [Full Text] [Related]

  • 13. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
    Dirven L, van den Bent MJ, Bottomley A, van der Meer N, van der Holt B, Vos MJ, Walenkamp AM, Beerepoot LV, Hanse MC, Reijneveld JC, Otten A, de Vos FY, Smits M, Bromberg JE, Taal W, Taphoorn MJ, Dutch Neuro-Oncology Group (LWNO).
    Eur J Cancer; 2015 Jul 23; 51(10):1321-30. PubMed ID: 25899986
    [Abstract] [Full Text] [Related]

  • 14. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
    Parasramka S, Talari G, Rosenfeld M, Guo J, Villano JL.
    Cochrane Database Syst Rev; 2017 Jul 26; 7(7):CD011773. PubMed ID: 28744879
    [Abstract] [Full Text] [Related]

  • 15. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
    Peters KB, Lipp ES, Miller E, Herndon JE, McSherry F, Desjardins A, Reardon DA, Friedman HS.
    J Neurooncol; 2018 Apr 26; 137(2):349-356. PubMed ID: 29264836
    [Abstract] [Full Text] [Related]

  • 16. Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.
    Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Cañete A, Saran F, Le Deley MC, Varlet P, Morgan PS, Jaspan T, Jones C, Giangaspero F, Smith H, Garcia J, Elze MC, Rousseau RF, Abrey L, Hargrave D, Vassal G.
    J Clin Oncol; 2018 Apr 01; 36(10):951-958. PubMed ID: 29412784
    [Abstract] [Full Text] [Related]

  • 17. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
    Andre T, Amonkar M, Norquist JM, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Sevilla I, De La Fouchardiere C, Rivera F, Elez E, Diaz LA, Yoshino T, Van Cutsem E, Yang P, Farooqui M, Le DT.
    Lancet Oncol; 2021 May 01; 22(5):665-677. PubMed ID: 33812497
    [Abstract] [Full Text] [Related]

  • 18. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
    Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R.
    Lancet Oncol; 2016 Nov 01; 17(11):1521-1532. PubMed ID: 27686946
    [Abstract] [Full Text] [Related]

  • 19. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
    Zhu JJ, Demireva P, Kanner AA, Pannullo S, Mehdorn M, Avgeropoulos N, Salmaggi A, Silvani A, Goldlust S, David C, Benouaich-Amiel A, Zvi Ram on behalf of the EF-14 Trial Investigators.
    J Neurooncol; 2017 Dec 01; 135(3):545-552. PubMed ID: 28849310
    [Abstract] [Full Text] [Related]

  • 20. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
    Weller J, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Hau P, Krex D, Grauer O, Goldbrunner R, Bähr O, Uhl M, Seidel C, Tabatabai G, Brehmer S, Bullinger L, Galldiks N, Schaub C, Kebir S, Stummer W, Simon M, Fimmers R, Coch C, Glas M, Herrlinger U, Schäfer N.
    Lancet Oncol; 2019 Oct 01; 20(10):1444-1453. PubMed ID: 31488360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.